You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR OXSORALEN-ULTRA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for OXSORALEN-ULTRA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00005092 ↗ Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Completed National Cancer Institute (NCI) Phase 1 1999-05-28 RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells are rejected by the body's normal tissues. Transplanting donated cells that have been treated with psoralen may prevent this from happening. PURPOSE: Phase I trial to study the effectiveness of chemotherapy, radiation therapy, and psoralen-treated donor cells in treating patients who are undergoing peripheral stem cell transplantation for hematologic cancer.
NCT00005092 ↗ Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Completed M.D. Anderson Cancer Center Phase 1 1999-05-28 RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy used to kill tumor cells. Sometimes the transplanted cells are rejected by the body's normal tissues. Transplanting donated cells that have been treated with psoralen may prevent this from happening. PURPOSE: Phase I trial to study the effectiveness of chemotherapy, radiation therapy, and psoralen-treated donor cells in treating patients who are undergoing peripheral stem cell transplantation for hematologic cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for OXSORALEN-ULTRA

Condition Name

Condition Name for OXSORALEN-ULTRA
Intervention Trials
Leukemia 1
Lymphoma 1
Multiple Myeloma and Plasma Cell Neoplasm 1
Myelodysplastic Syndromes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for OXSORALEN-ULTRA
Intervention Trials
Multiple Myeloma 1
Lymphoma 1
Syndrome 1
Leukemia 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for OXSORALEN-ULTRA

Trials by Country

Trials by Country for OXSORALEN-ULTRA
Location Trials
United States 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for OXSORALEN-ULTRA
Location Trials
Texas 1
Missouri 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for OXSORALEN-ULTRA

Clinical Trial Phase

Clinical Trial Phase for OXSORALEN-ULTRA
Clinical Trial Phase Trials
Phase 1 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for OXSORALEN-ULTRA
Clinical Trial Phase Trials
Completed 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for OXSORALEN-ULTRA

Sponsor Name

Sponsor Name for OXSORALEN-ULTRA
Sponsor Trials
National Cancer Institute (NCI) 1
M.D. Anderson Cancer Center 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for OXSORALEN-ULTRA
Sponsor Trials
NIH 1
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.